Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18922371 | METHODS FOR TREATMENT USING ANTI-ALPHA4BETA7 ANTIBODY | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18815390 | FUSION PROTEIN COMPRISING ANTI-CD73 ANTIBODY AND IL-2, AND USE THEREOF | August 2024 | May 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 18750999 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | June 2025 | Abandon | 12 | 0 | 1 | No | No |
| 18750887 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | June 2025 | Abandon | 12 | 0 | 1 | No | No |
| 18750908 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | June 2024 | April 2025 | Abandon | 10 | 1 | 0 | No | No |
| 18745750 | ANTI-RECEPTOR EXPRESSED ON LYMPHOID TISSUES (RELT) RECOMBINANT MONOCLONAL ANTIBODY AND PREPARATION METHOD AND USE THEREOF | June 2024 | November 2024 | Allow | 5 | 1 | 0 | Yes | No |
| 18733287 | Anti-DLL3 Antibodies and Uses Thereof | June 2024 | April 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18607180 | ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN AND USE THEREOF | March 2024 | August 2024 | Allow | 5 | 1 | 0 | No | No |
| 18588667 | COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS | February 2024 | May 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18414799 | COMPLEMENT COMPONENT C5 ANTIBODIES | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18403218 | INHIBITORS OF COMPLEMENT FACTOR H | January 2024 | December 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18394365 | TREATMENT OF CARDIOMETABOLIC DISEASE WITH INHIBITORS OF TYPE I INTERFERON SIGNALLING | December 2023 | May 2025 | Allow | 17 | 2 | 1 | Yes | No |
| 18492125 | PLK1 INHIBITOR IN COMBINATION WITH ANTI-ANGIOGENICS FOR TREATING METASTATIC CANCER | October 2023 | January 2025 | Abandon | 15 | 2 | 1 | Yes | No |
| 18480153 | TNF-ALPHA IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS | October 2023 | March 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18472144 | MONOCLONAL ANTIBODY AGAINST HUMAN LAG-3, METHOD FOR PREPARING THE SAME, AND USE THEREOF | September 2023 | April 2025 | Allow | 19 | 1 | 1 | Yes | No |
| 18354934 | CD1a ANTIBODIES AND USES THEREOF | July 2023 | June 2025 | Allow | 22 | 1 | 1 | Yes | No |
| 18354611 | TREATING CANCER BY BLOCKING THE INTERACTION OF TIM-3 AND ITS LIGAND | July 2023 | April 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18349027 | ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF | July 2023 | April 2025 | Allow | 22 | 1 | 1 | No | No |
| 18344711 | IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES | June 2023 | June 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18341202 | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L-RELATED DISEASES OR DISORDERS | June 2023 | December 2024 | Allow | 17 | 1 | 0 | Yes | No |
| 18338946 | ANTI-PAR-2 ANTIBODIES AND METHODS OF USE THEREOF | June 2023 | April 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18333869 | METHODS FOR TARGETING THE IMMUNE CHECKPOINT PD1 PATHWAY FOR TREATING PULMONARY FIBROSIS | June 2023 | February 2025 | Allow | 20 | 1 | 1 | No | No |
| 18331623 | HUMANIZED ANTI-N-CADHERIN ANTIBODIES AND USES THEREOF | June 2023 | March 2025 | Abandon | 21 | 0 | 2 | No | No |
| 18321711 | MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR, AND ENCODING GENE AND USE THEREOF | May 2023 | February 2025 | Abandon | 21 | 1 | 0 | No | No |
| 18296265 | ANTI-PCSK9 ANTIBODIES | April 2023 | November 2024 | Allow | 20 | 1 | 0 | No | No |
| 18193889 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 | March 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18187475 | MONOCLONAL ANTIBODIES TO CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4 (CTLA-4) | March 2023 | October 2024 | Allow | 19 | 2 | 0 | Yes | No |
| 18022113 | ANTIBODY SPECIFICALLY BOUND TO GLYCOSYLATED CEACAM5 | February 2023 | February 2024 | Allow | 12 | 1 | 1 | Yes | No |
| 18170742 | ANTIBODIES TO INTEGRIN AVB6 AND USE OF SAME TO TREAT CANCER | February 2023 | November 2024 | Abandon | 21 | 0 | 1 | No | No |
| 18097078 | MONOCLONAL ANTIBODY AND ANTIGENS FOR DIAGNOSING AND TREATING LUNG DISEASE AND INJURY | January 2023 | January 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18153277 | NEUTRALIZING ANTIBODIES TO THE ALPHA V BETA 8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY | January 2023 | April 2024 | Allow | 16 | 0 | 0 | No | No |
| 18153103 | ANTIBODIES THAT BIND INTEGRIN AVB8 AND USES THEREOF | January 2023 | September 2024 | Allow | 20 | 1 | 1 | Yes | No |
| 18091145 | METHOD FOR DETECTING OR TREATING TRIPLE NEGATIVE BREAST CANCER | December 2022 | April 2025 | Allow | 27 | 4 | 0 | Yes | No |
| 18146951 | METHODS OF TREATMENT BY TARGETING VCAM1 AND MAEA | December 2022 | August 2024 | Allow | 19 | 1 | 0 | No | No |
| 18084618 | ISOLATED POLYPEPTIDES OF CD44 AND USES THEREOF | December 2022 | February 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18064663 | COMPOSITIONS AND METHODS FOR TREATING CANCER WITH A COMBINATION OF AN ANTAGONIST OF PD-1 AND AN ANTI-CTLA4 ANTIBODY | December 2022 | May 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17999444 | TNF-ALPHA IMMUNOCONJUGATE THERAPY FOR THE TREATMENT OF BRAIN TUMORS | November 2022 | August 2023 | Allow | 9 | 2 | 0 | Yes | No |
| 18056825 | COLLAGEN-LOCALIZED IMMUNOMODULATORY MOLECULES AND METHODS THEREOF | November 2022 | December 2024 | Allow | 25 | 2 | 1 | Yes | No |
| 17980751 | NOVEL PEPTIDES | November 2022 | October 2023 | Allow | 12 | 1 | 1 | Yes | No |
| 18050817 | ANTI-ALPHA-V INTEGRIN ANTIBODY FOR THE TREATMENT OF FIBROSIS AND/OR FIBROTIC DISORDERS | October 2022 | April 2024 | Allow | 18 | 1 | 0 | Yes | No |
| 17975865 | ANTI-NR10 ANTIBODY AND USE THEREOF | October 2022 | July 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17995168 | FULLY HUMAN ANTI-HUMAN CD22 CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF | September 2022 | June 2025 | Allow | 33 | 0 | 0 | Yes | No |
| 17931386 | Anti-Abeta Antibodies | September 2022 | May 2025 | Abandon | 32 | 2 | 1 | No | No |
| 17930704 | ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF | September 2022 | March 2025 | Abandon | 30 | 1 | 1 | No | No |
| 17819287 | ANTIBODIES AGAINST OX-40 AND USES THEREOF | August 2022 | October 2024 | Abandon | 26 | 1 | 1 | No | No |
| 17869872 | ROR1 ANTIBODIES | July 2022 | November 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17813375 | HUMAN ANTI-SEMAPHORIN 4D ANTIBODY | July 2022 | January 2024 | Allow | 18 | 1 | 0 | No | No |
| 17844484 | MATERIALS AND METHODS FOR HINGE REGIONS IN FUNCTIONAL EXOGENOUS RECEPTORS | June 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17836457 | Anti-IL1RAP antibody | June 2022 | April 2024 | Allow | 22 | 1 | 1 | Yes | No |
| 17833077 | ANTIBODY DRUG CONJUGATES FOR ABLATING HEMATOPOIETIC STEM CELLS | June 2022 | August 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17767171 | CONNEXIN 43 ANTIBODIES AND USE THEREOF | April 2022 | August 2024 | Allow | 28 | 1 | 0 | Yes | No |
| 17689869 | CD8A-Binding Fibronectin Type III Domains | March 2022 | November 2023 | Allow | 20 | 0 | 1 | Yes | No |
| 17592227 | INTEGRIN BETA7 ANTAGONISTS AND METHODS OF TREATING CROHN'S DISEASE | February 2022 | March 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17592154 | METHODS OF ADMINISTERING BETA7 INTEGRIN ANTAGONISTS | February 2022 | March 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17586662 | ANTI-ANGPTL3 ANTIBODIES AND USES THEREOF | January 2022 | February 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17578294 | ADMINISTRATION OF AGENTS FOR THE TREATMENT OF INFLAMMATION | January 2022 | March 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17571286 | METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR | January 2022 | October 2024 | Abandon | 33 | 1 | 1 | No | No |
| 17563502 | ANTI-PD-L1 ANTIBODIES AND USES THEREOF | December 2021 | January 2024 | Abandon | 25 | 0 | 1 | No | No |
| 17557898 | ENGINEERED ANTIBODY FOR INHIBITION OF FIBROSIS | December 2021 | February 2024 | Abandon | 26 | 1 | 0 | No | No |
| 17552486 | USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS | December 2021 | February 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17552211 | USE OF BIOMARKERS FOR ASSESSING TREATMENT OF GASTROINTESTINAL INFLAMMATORY DISORDERS WITH BETA7 INTEGRIN ANTAGONISTS | December 2021 | February 2024 | Abandon | 26 | 0 | 1 | No | No |
| 17537275 | METHODS FOR TREATING OR PREVENTING ATHEROSCLEROSIS BY ADMINISTERING AN INHIBITOR OF ANGPTL3 | November 2021 | April 2025 | Abandon | 41 | 2 | 1 | No | No |
| 17532664 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME | November 2021 | March 2025 | Abandon | 40 | 3 | 1 | No | No |
| 17532660 | ANTI-TM4SF1 ANTIBODIES AND METHODS OF USING SAME | November 2021 | December 2024 | Abandon | 37 | 3 | 0 | No | No |
| 17454837 | COMBINATION THERAPIES USING ANTI-PSEUDOMONAS PSL AND PCRV BINDING MOLECULES | November 2021 | June 2025 | Allow | 43 | 2 | 0 | Yes | No |
| 17610328 | BINDING MOLECULES | November 2021 | June 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17520480 | PROTEIN BINDING TO FIBRONECTIN B DOMAIN | November 2021 | January 2024 | Allow | 26 | 1 | 1 | Yes | No |
| 17512500 | Methods and Compositions for Improving Antiangiogenic Therapy with Anti-Integrins | October 2021 | February 2025 | Abandon | 39 | 2 | 1 | No | No |
| 17511343 | Inhibition of Tau Propagation | October 2021 | June 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17452042 | HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS | October 2021 | January 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17506667 | ANTI-SEMA3A ANTIBODIES AND THEIR USES FOR TREATING A THROMBOTIC DISEASE OF THE RETINA | October 2021 | July 2024 | Abandon | 33 | 2 | 0 | Yes | Yes |
| 17503592 | ANTIBODIES TO CANINE AND FELINE ONCOSTATIN M RECEPTOR BETA AND USES THEREOF | October 2021 | August 2024 | Allow | 34 | 2 | 1 | No | No |
| 17496664 | ANTI-INTEGRIN BETA-1 ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF | October 2021 | July 2024 | Abandon | 33 | 1 | 1 | Yes | No |
| 17441861 | MAGE A4 T CELL RECEPTORS | September 2021 | February 2025 | Allow | 41 | 0 | 1 | No | No |
| 17439971 | EXPANDED NK CELL FRACTIONS FOR TRANSPLANTATION IN COMBINATION THERAPY | September 2021 | April 2025 | Allow | 42 | 1 | 0 | No | No |
| 17474359 | SH3YL1 Antibodies, Compositions Comprising the Same, and Vectors and Uses Thereof | September 2021 | July 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17475214 | USE OF ANTI-FAM19A5 ANTIBODIES FOR TREATING FIBROSIS | September 2021 | April 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17458019 | METHODS OF INHIBITING COMPLEMENT FACTOR H (CFH) COMPRISING ADMINISTERING AN ANTIBODY THAT BINDS CFH | August 2021 | December 2022 | Allow | 15 | 1 | 1 | Yes | No |
| 17406611 | COMPOSITIONS TARGETING THE SOLUBLE EXTRACELLULAR DOMAIN OF E-CADHERIN AND RELATED METHODS FOR CANCER THERAPY | August 2021 | December 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17399725 | ANTIBODY TO FIBROSIS-RELATED MOLECULE AND MEDICAL APPLICATION THEREOF | August 2021 | August 2023 | Allow | 24 | 1 | 0 | No | No |
| 17396517 | CHIMERIC ANTIGEN RECEPTORS COMPRISING BCMA-SPECIFIC FIBRONECTIN TYPE III DOMAINS AND USES THEREOF | August 2021 | November 2023 | Abandon | 27 | 1 | 0 | No | No |
| 17395372 | ANTAGONISTS OF ACTIVIN-ACTRIIA AND USES FOR INCREASING RED BLOOD CELL LEVELS | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17395365 | ACTIVIN-ACTRII ANTAGONISTS AND USES FOR INCREASING RED BLOOD CELL LEVELS | August 2021 | October 2023 | Abandon | 26 | 0 | 1 | No | No |
| 17392740 | ANTI-IDIOTYPE ANTIBODIES TARGETING ANTI-CD70 CHIMERIC ANTIGEN RECEPTOR | August 2021 | June 2023 | Allow | 23 | 1 | 1 | Yes | No |
| 17376830 | ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-KLK2 ANTIBODIES | July 2021 | February 2024 | Allow | 31 | 2 | 1 | Yes | No |
| 17369670 | MODULATION OF LEUKOCYTE ACTIVITY IN TREATMENT OF NEUROINFLAMMATORY DEGENERATIVE DISEASE | July 2021 | October 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17350763 | DOPPEL-TARGETING ANTIBODIES | June 2021 | October 2023 | Allow | 28 | 1 | 1 | Yes | No |
| 17312083 | ANTIBODY SPECIFICALLY BINDING TO ICAM-1 AND USE THEREOF | June 2021 | January 2025 | Allow | 44 | 1 | 0 | Yes | No |
| 17338991 | Antibodies to MAdCAM | June 2021 | June 2023 | Allow | 25 | 1 | 0 | No | No |
| 17307709 | COMPOSITIONS AND METHODS OF TREATING SARCOMA LUNG METASTASIS | May 2021 | October 2023 | Allow | 29 | 2 | 1 | Yes | No |
| 17306544 | INHIBITING ANTI-ENPP1 ANTIBODIES | May 2021 | July 2023 | Allow | 27 | 1 | 1 | Yes | No |
| 17239512 | TREATMENT WITH ANTI-ALPHA4BETA7 ANTIBODY | April 2021 | December 2024 | Allow | 44 | 1 | 2 | Yes | No |
| 17236810 | HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODIES TO CD47 | April 2021 | July 2023 | Allow | 26 | 1 | 0 | Yes | No |
| 17301741 | ANTI-TENASCIN C ANTIBODIES AND USES THEREOF | April 2021 | July 2023 | Allow | 27 | 1 | 0 | No | No |
| 17208014 | ANTIBODY | March 2021 | October 2024 | Abandon | 43 | 4 | 0 | No | No |
| 17194054 | Methods of Inhibiting MASP-2 for the Treatment and/or Prevention of Coronavirus-induced Acute Respiratory Distress Syndrome | March 2021 | February 2025 | Allow | 47 | 3 | 1 | No | No |
| 17184116 | METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS | February 2021 | April 2025 | Allow | 49 | 2 | 1 | Yes | Yes |
| 17177179 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND PCSK9 | February 2021 | August 2023 | Allow | 30 | 1 | 1 | No | No |
| 17175913 | ANTIBODIES AGAINST MAC-1 | February 2021 | January 2024 | Abandon | 35 | 3 | 0 | Yes | No |
| 17174610 | Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders | February 2021 | October 2024 | Abandon | 44 | 0 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner HADDAD, MAHER M.
With a 80.0% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 40.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner HADDAD, MAHER M works in Art Unit 1641 and has examined 313 patent applications in our dataset. With an allowance rate of 78.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 32 months.
Examiner HADDAD, MAHER M's allowance rate of 78.6% places them in the 39% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by HADDAD, MAHER M receive 1.90 office actions before reaching final disposition. This places the examiner in the 60% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by HADDAD, MAHER M is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +39.9% benefit to allowance rate for applications examined by HADDAD, MAHER M. This interview benefit is in the 89% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 23.9% of applications are subsequently allowed. This success rate is in the 24% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 59.0% of cases where such amendments are filed. This entry rate is in the 81% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 89.1% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 82.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 65.1% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 10.5% of allowed cases (in the 96% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.3% of allowed cases (in the 73% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.